Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Widely recognized as a global leader in strategic transactions, with bench strength in the U.S., Europe and Asia, Covington advises on many of the industry's largest and most innovative life sciences transactions year after year. We leverage extensive cross-border experience and a deep understanding of industry-specific regulatory, IP and commercial considerations to craft comprehensive, practical and forward-looking solutions across the full range of strategic and commercial transactions.

Our corporate practice is consistently recognized for excellence by Chambers, Legal 500, and Corporate Board Member, and our life sciences industry group is ranked in the top tier for transactional, regulatory, IP and litigation capabilities around the world by Chambers, Legal 500, Law 360 and LMG Life Sciences. Our life sciences transactional practice integrates these industry leading capabilities to meet the specialized needs of life sciences companies.

Collaborations, Licensing and Commercial Agreements

A hallmark of our transactional practice is our experience structuring, negotiating, and drafting strategic collaboration, licensing, co-development, co-promotion, technology transfer and various types of commercial agreements, ranging from highly-complex global alliances to more standard licensing agreements.

We work collaboratively with our clients to develop pragmatic, flexible agreements that promote productive and lasting relationships by focusing on the shared business goals of all parties.

We have completed numerous cross-border and other corporate partnering deals for clients throughout the world. Our extensive work for established pharmaceutical and biotech companies gives us a deep understanding of later-stage and commercial agreements as well as complex research and discovery alliances. We have assisted with preparing standard agreement forms for co-promotion, contract sales force, distribution, and authorized generic deals, and are regularly called upon to provide benchmarking advice, as well as to assist with restructuring and unwinding troubled or underperforming relationships negotiated by other firms.

Mergers & Acquisitions

Covington’s mergers and acquisitions team represents pharmaceutical, specialty pharmaceutical, biotech and medical device companies in public and private acquisitions and dispositions globally. Overall, over the last few years, Covington’s mergers and acquisition team has represented clients in and outside of the life science industry in over 500 completed transactions with an aggregate value in excess of $500 billion. We provide thorough and sophisticated analysis of the agreements, regulatory issues and IP rights that are central to M&A transactions in the life sciences industry. Our M&A lawyers understand the sometimes fluid nature of transactions in the life sciences sector, and have considerable experience working across disciplines on dual-track transactions and advising on deals as they evolve from acquisitions or dispositions to arrangements that are more collaborative in nature.

Royalty Monetizations

Covington has a highly sophisticated royalty monetization practice dedicated to helping universities, life sciences companies and other institutions manage risk, raise capital, and maximize the value of their intellectual property assets. We are widely recognized as a leader in this very specialized field and have advised on royalty monetization transactions with an aggregate value in excess of $3 billion. Covington's deep experience in royalty monetizations has given us an understanding of, and familiarity with, the perspectives and requirements of the participants in this novel and growing market and allows us to help our clients design structures to successfully and efficiently implement these unique and complex transactions.

  • The only firm recognized by Chambers as a “Band 1” firm for Life Sciences across their U.S., UK, Europe, China and Global surveys
  • Awarded “Life Sciences Practice Group of the Year” by Law360 in 2012, 2013, 2014, 2015, and 2016.
  • Recognized as a leading life sciences law firm by Chambers, Legal 500, Law360 and LMG Life Sciences
  • More than a dozen transactional lawyers individually recognized for excellence specifically in the life sciences industry by Chambers, Legal 500 and LMG Life Sciences